Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune hemolytic anemia and IgG4-related…Read More

You might also be interested in reading Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results.